Related Experiment Video
Updated: Jul 5, 2025
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
Finding the PSA-based screening stopping age using prostate cancer risk
Azin Nahvijou1, Mohammad Hadian2, Naser Mohamadkhani2
1Cancer Research Center of Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Cancer Treatment and Research Communications
|January 24, 2024
Summary
Prostate cancer screening should be personalized. Stopping age depends on individual risk and other health conditions, with screening generally not recommended after age 70 or for those with severe comorbidities.
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Prostate cancer screening decisions are complex, balancing benefits against harms like pain and cost.
- Current screening methods, including Prostate-Specific Antigen (PSA) tests, have limitations and are not universally recommended after a certain age.
- Identifying an optimal age to stop prostate cancer screening can reduce economic burden and unnecessary procedures.
Purpose of the Study:
- To develop a model for determining the optimal age to stop prostate cancer screening.
- To investigate how individual prostate cancer risk and the presence of comorbidities influence this stopping age.
Main Methods:
- Utilized a Markov model to simulate prostate cancer progression and determine optimal screening cessation.
- Analyzed the interplay between prostate cancer risk factors, comorbidity burden, and the recommended age to discontinue screening.
Main Results:
- The optimal age to stop prostate cancer screening increases with higher prostate cancer risk and greater comorbidity effects.
- Screening cessation is advised before age 70.
- For men with significant comorbidities like stroke or heart disease, prostate cancer screening is not recommended at any age.
Conclusions:
- Personalizing prostate cancer screening by considering individual risk factors enhances efficiency.
- Factors such as race, family history, and prior PSA levels are important for risk stratification and determining stopping age.
- The severity of comorbidities is a critical determinant in the decision-making process for stopping prostate cancer screening.
Related Concept Videos
01:20Disorders of the Male Reproductive System
419
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
419
01:28Menopause
166
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
166